Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market : Segmental Highlights and Table of Content (2014 - 2020)

The incidence of healthcare associated pneumonia or global hospital-acquired pneumonia drugs market is showing a progressive increase; however, the multidrug resistance shown by microorganisms that cause nosocomial infections has created a large market for drugs that treat hospital-acquired pneumonia. According to the report, six major phase III drugs will collectively generate revenue to the tune of US$3.8 bn by 2020.These findings are detailed in the report, titled ‘Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.’

The global protein expression technology market is segmented on the basis Hospital Acquired Pneumonia Drug Pipeline, Late Stage Candidates (Phase III) , Acquired Pneumonia Drug Pipeline, Early Stage Candidates (Phase II, Phase I and Preclinical Trials)

Report Overview and TOC @ https://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html

Hospital-acquired pneumonia, which is also sometimes referred to as ventilator-associated pneumonia, is typically seen among patients who are immunocompromised patients, on enteral feeding, or have undergone surgery. Infants, too, face a risk of acquiring hospital-acquired pneumonia. Among the newborn, respiratory syncytial virus (RSV) is identified as being the major cause of nosocomial pneumonia.

The global hospital-acquired pneumonia drugs market currently features one vaccine and five investigational drugs in clinical trials phase III. It is estimated that many of these drugs will hit the market in 2017. The following drugs are currently in phase III of clinical trials, as per the report: Cubist Pharmaceuticals’ Ceftolozane/tazobactam and tedizolid phosphate, AstraZeneca PLC’s Ceftazidime/avibactam, Bayer Healthcare’s Amikacin inhale, Achaogen, Inc.’s Plazomicin, and GlaxoSmithKline’s Synflorix. Of these, tedizolid phosphate is emerging as the most preferred drug for treating nosocomial pneumonia.

Request A Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881

Summary of Table of Content
1 Introduction
2 Executive Summary
3 Market overview
4 Hospital Acquired Pneumonia, Pipeline Analysis
5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography
6 Recommendations
7 Company Profiles

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1881

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Transparency Market Research

State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

This release was published on openPR.